Retatrutide remains an experimental medication still in Phase 3 clinical trials
Biosion Biosion most recently (Nov 2024) did a deal with Aclaris Therapeutics for out-license of their long half life TSLP antibody, bosakitug
When they first isolated it, the scientists in Zagreb did not have the tools to fully characterize it
Some 22.9% of people receiving the 7.2 mg Wegovy dose experienced dysaesthesia, painful, burning, or tingling sensations, compared to 6% receiving the 2.4mg dose and 0.5% who were given a placebo
Mezclar medicamentos y suplementos dietticos puede poner en peligro su salud
ADR: Major- GI No hepatic or renal adjustment Has not been studied in patients with history of pancreatitis Boxed Warning: Risk of thyroid C-cell tumors Note: The combined use of GLP-1 RAs, Tirzepatide, and/or DPP-4 Inhibitors (eg, Sitagliptan) NOT recommended due to their similar MOA